Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, Sanabria Bohorquez SM, Anania VG, Wildsmith KR, Schauer SP, Lee J, Dolton MJ, Ramakrishnan V, Abramzon D, Teng E; Lauriet investigators. Monteiro C, et al. Among authors: ramakrishnan v. Neurology. 2023 Oct 3;101(14):e1391-e1401. doi: 10.1212/WNL.0000000000207663. Epub 2023 Aug 29. Neurology. 2023. PMID: 37643887 Free PMC article. Clinical Trial.
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigators. Teng E, et al. Among authors: ramakrishnan v. JAMA Neurol. 2022 Aug 1;79(8):758-767. doi: 10.1001/jamaneurol.2022.1375. JAMA Neurol. 2022. PMID: 35696185 Free PMC article. Clinical Trial.
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates.
Ramakrishnan V, Friedrich C, Witt C, Sheehan R, Pryor M, Atwal JK, Wildsmith K, Kudrycki K, Lee SH, Mazer N, Hofmann C, Fuji RN, Jin JY, Ramanujan S, Dolton M, Quartino A. Ramakrishnan V, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Jan;12(1):62-73. doi: 10.1002/psp4.12876. Epub 2022 Nov 6. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36281062 Free PMC article.
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
Jamalian S, Dolton M, Chanu P, Ramakrishnan V, Franco Y, Wildsmith K, Manser P, Teng E, Jin JY, Quartino A, Hsu JC; Alzheimer's Disease Neuroimaging Initiative. Jamalian S, et al. Among authors: ramakrishnan v. CPT Pharmacometrics Syst Pharmacol. 2023 Jul;12(7):1029-1042. doi: 10.1002/psp4.12974. Epub 2023 May 2. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37101394 Free PMC article.
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.
Schauer SP, Toth B, Lee J, Honigberg LA, Ramakrishnan V, Jiang J, Kollmorgen G, Bayfield A, Wild N, Hoffman J, Ceniceros R, Dolton M, Bohórquez SMS, Hoogenraad CC, Wildsmith KR, Teng E, Monteiro C, Anania V, Yeh FL. Schauer SP, et al. Among authors: ramakrishnan v. Alzheimers Dement. 2024 Nov 8. doi: 10.1002/alz.14346. Online ahead of print. Alzheimers Dement. 2024. PMID: 39513754
A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers.
Jones NS, Kshirsagar S, Mohanan V, Ramakrishnan V, Di Nucci F, Ma L, Mao J, Ding H, Klabunde S, Vucic D, Pan L, Lekkerkerker AN, Chen Y, Rothenberg ME. Jones NS, et al. Among authors: ramakrishnan v. Clin Transl Sci. 2023 Oct;16(10):1997-2009. doi: 10.1111/cts.13607. Epub 2023 Aug 24. Clin Transl Sci. 2023. PMID: 37596814 Free PMC article. Clinical Trial.
Hallmarks of neurodegenerative disease: A systems pharmacology perspective.
Bloomingdale P, Karelina T, Ramakrishnan V, Bakshi S, Véronneau-Veilleux F, Moye M, Sekiguchi K, Meno-Tetang G, Mohan A, Maithreye R, Thomas VA, Gibbons F, Cabal A, Bouteiller JM, Geerts H. Bloomingdale P, et al. Among authors: ramakrishnan v. CPT Pharmacometrics Syst Pharmacol. 2022 Nov;11(11):1399-1429. doi: 10.1002/psp4.12852. Epub 2022 Aug 17. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35894182 Free PMC article. Review.
1,099 results